PrimeraDx receives its fourth patent

PrimeraDx, Inc., a privately held molecular diagnostics company, announced today that it has received its fourth patent. The patent, entitled “Methods and systems for dynamic gene expression profiling”, with inventor Vladimir Slepnev, Ph.D., describes a novel method of quantitative analysis of gene expression allowing simultaneous interrogation of multiple genes in a single tube reaction. The invention provides methods and compositions for transcription profiling of multiple samples enabling the identification of differentially expressed genes and their quantitative assessment. The patented process allows identification of disease-associated changes in gene expression signatures making it broadly applicable for assaying panels of diagnostic biomarkers.

"The receipt of this patent strengthens our estate by adding key protection in the area of quantitative multiplexed analysis of gene expression. It enables, from a single tube reaction, the measurement of complex gene signatures that will play a major role in future cancer diagnostics”, said Martin L. Verhoef, president and chief executive officer of PrimeraDx, Inc.